[go: up one dir, main page]

WO2024044755A3 - Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof - Google Patents

Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof Download PDF

Info

Publication number
WO2024044755A3
WO2024044755A3 PCT/US2023/072918 US2023072918W WO2024044755A3 WO 2024044755 A3 WO2024044755 A3 WO 2024044755A3 US 2023072918 W US2023072918 W US 2023072918W WO 2024044755 A3 WO2024044755 A3 WO 2024044755A3
Authority
WO
WIPO (PCT)
Prior art keywords
ehsp90
hsp90
extracellular hsp90
extracellular
targeted radiopharmaceuticals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/072918
Other languages
French (fr)
Other versions
WO2024044755A2 (en
Inventor
Hari Krishna R. Santhapuram
Iontcho R. Vlahov
William Leslie Turnbull
Brigitte Lise THÉRIAULT
Stuart James MAHONEY
Samuel Kunjunju KUTTY
Christopher Paul Leamon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Pharmaceuticals Inc
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of WO2024044755A2 publication Critical patent/WO2024044755A2/en
Publication of WO2024044755A3 publication Critical patent/WO2024044755A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Conjugates comprising a targeting moiety that specifically binds to HSP90, in particular, extracellular HSP90, covalently linked to chelator selected from DOTA, DOTAGA, NOTA, and NODAGA, where the conjugate further comprises a radionuclide chelated by the chelator thereof. Also disclosed are pharmaceutical compositions and methods of treating cancer with the same.
PCT/US2023/072918 2022-08-26 2023-08-25 Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof Ceased WO2024044755A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263401227P 2022-08-26 2022-08-26
US63/401,227 2022-08-26

Publications (2)

Publication Number Publication Date
WO2024044755A2 WO2024044755A2 (en) 2024-02-29
WO2024044755A3 true WO2024044755A3 (en) 2024-08-02

Family

ID=90014114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/072918 Ceased WO2024044755A2 (en) 2022-08-26 2023-08-25 Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof

Country Status (3)

Country Link
AR (1) AR130317A1 (en)
TW (1) TW202416974A (en)
WO (1) WO2024044755A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202448870A (en) * 2023-04-14 2024-12-16 加拿大商融合製藥公司 Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof
WO2024212001A1 (en) * 2023-04-14 2024-10-17 Fusion Pharmaceuticals Inc. 2,4-dihyroxy-5-isopropylphenyl derivatives and pharmaceutical compositions thereof effective as extracellular hsp90, (ehsp90)-targeted radiopharmaceuticals useful in the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113447A1 (en) * 2008-08-08 2010-05-06 Burlison Joseph A Triazole compounds that modulate hsp90 activity
US20220184217A1 (en) * 2019-04-03 2022-06-16 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113447A1 (en) * 2008-08-08 2010-05-06 Burlison Joseph A Triazole compounds that modulate hsp90 activity
US20220184217A1 (en) * 2019-04-03 2022-06-16 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LO PUI-CHI, RODRÍGUEZ-MORGADE M. SALOMÉ, PANDEY RAVINDRA K., NG DENNIS K. P., TORRES TOMÁS, DUMOULIN FABIENNE: "The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer", CHEMICAL SOCIETY REVIEWS, ROYAL SOCIETY OF CHEMISTRY, UK, vol. 49, no. 4, 24 February 2020 (2020-02-24), UK , pages 1041 - 1056, XP093198277, ISSN: 0306-0012, DOI: 10.1039/C9CS00129H *

Also Published As

Publication number Publication date
TW202416974A (en) 2024-05-01
AR130317A1 (en) 2024-11-27
WO2024044755A2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
ES2952017T3 (en) Improved antibody-oligonucleotide conjugate
WO2024044755A3 (en) Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof
Alley et al. The pharmacologic basis for antibody-auristatin conjugate activity
Hagemann et al. In vitro and in vivo efficacy of a novel CD33-targeted thorium-227 conjugate for the treatment of acute myeloid leukemia
PH12021550692A1 (en) Conjugation linkers containing 2,3-diaminosuccinyl group
WO2004073656A3 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU3057297A (en) Targeted combination immunotherapy of cancer
CA2495795A1 (en) Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
AR069747A1 (en) ANTI-B7H4 MONOCLONAL ANTIBODY CONJUGATE - PHARMACO AND METHODS OF USE
MX2021010003A (en) HIGH AFFINITY ANTI-MERTK ANTIBODIES AND THEIR USES.
US20190216945A1 (en) Antibody-polymer-drug conjugates
MX2024014345A (en) Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
MX2022015147A (en) Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereof.
US20240293588A1 (en) Therapeutic conjugates
Kitson et al. Antibody-drug conjugates (ADCs)–biotherapeutic bullets
CA3198996A1 (en) Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023014988A8 (en) Conjugates comprising covalent binders for targeting intracellular proteins
WO2021142258A8 (en) Macrocyclic chelates and uses thereof
Govindan et al. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies
WO2022194988A3 (en) B-lymphocyte specific amatoxin antibody conjugates
Trembleau et al. Development of 18 F-fluorinatable dendrons and their application to cancer cell targeting
WO2024073622A3 (en) Radiopharmaceutical compositions targeting ephrin type-a receptor 2 and uses thereof
MX2025004585A (en) Antibodies, antibody-drug conjugates, preparations and uses thereof
MX2022012821A (en) DIELS-ALDER CONJUGATION METHODS.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23858353

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23858353

Country of ref document: EP

Kind code of ref document: A2